Azacitidine for the treatment of relapsed and refractory AML in older patients
- 1 February 2015
- journal article
- clinical trial
- Published by Elsevier in Leukemia Research
- Vol. 39 (2) , 124-130
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Azacitidine in untreated acute myeloid leukemia: A report on 149 patientsAmerican Journal of Hematology, 2014
- Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blastsLeukemia Research, 2013
- Outcome of older patients with acute myeloid leukemia in first relapseAmerican Journal of Hematology, 2013
- Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutationBlood, 2013
- Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemiaBlood, 2012
- Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I TrialJournal of Clinical Oncology, 2012
- Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndromeOncotarget, 2010
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid LeukemiaJournal of Clinical Oncology, 2010
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetBlood, 2010
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyThe Lancet Oncology, 2009